Marshall Wace LLP Has $3.36 Million Holdings in Innoviva, Inc. (NASDAQ:INVA)

Marshall Wace LLP raised its position in Innoviva, Inc. (NASDAQ:INVA - Free Report) by 823.3% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 204,752 shares of the biotechnology company's stock after buying an additional 182,575 shares during the quarter. Marshall Wace LLP owned approximately 0.33% of Innoviva worth $3,358,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of INVA. SageView Advisory Group LLC purchased a new position in Innoviva during the first quarter worth about $1,555,000. Boston Partners increased its stake in Innoviva by 90.3% in the first quarter. Boston Partners now owns 391,456 shares of the biotechnology company's stock valued at $5,966,000 after purchasing an additional 185,784 shares during the last quarter. O Shaughnessy Asset Management LLC lifted its holdings in shares of Innoviva by 108.8% during the 1st quarter. O Shaughnessy Asset Management LLC now owns 73,066 shares of the biotechnology company's stock worth $1,114,000 after acquiring an additional 38,080 shares during the period. Victory Capital Management Inc. raised its stake in Innoviva by 63.1% during the second quarter. Victory Capital Management Inc. now owns 135,755 shares of the biotechnology company's stock worth $2,226,000 after purchasing an additional 52,523 shares during the period. Finally, BOKF NA raised its position in shares of Innoviva by 180.5% in the 2nd quarter. BOKF NA now owns 46,377 shares of the biotechnology company's stock worth $761,000 after buying an additional 29,846 shares during the period. Hedge funds and other institutional investors own 99.12% of the company's stock.

Innoviva Stock Performance

INVA traded down $0.06 during trading hours on Thursday, hitting $19.50. 1,175,599 shares of the stock were exchanged, compared to its average volume of 586,042. The company has a debt-to-equity ratio of 0.67, a current ratio of 12.70 and a quick ratio of 11.40. Innoviva, Inc. has a 12 month low of $12.22 and a 12 month high of $20.19. The stock has a 50-day simple moving average of $19.00 and a 200-day simple moving average of $16.88. The stock has a market cap of $1.22 billion, a price-to-earnings ratio of 8.78 and a beta of 0.57.

Innoviva (NASDAQ:INVA - Get Free Report) last posted its earnings results on Wednesday, July 31st. The biotechnology company reported $0.68 EPS for the quarter. The company had revenue of $99.90 million during the quarter. Innoviva had a return on equity of 33.26% and a net margin of 44.00%. Analysts anticipate that Innoviva, Inc. will post 0.5 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have recently commented on INVA. StockNews.com lowered shares of Innoviva from a "strong-buy" rating to a "buy" rating in a report on Tuesday, August 6th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Innoviva in a research note on Tuesday, July 30th.

Innoviva Profile

Innoviva, Inc engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.